Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 7, 2024
Deals

AstraZeneca, Hong Kong-based CSPC in deal for dyslipidemia therapy

Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

Better efficacy and safety could make Regeneron’s evinacumab the standard of care for HoFH
BioCentury | May 11, 2018
Finance

Amplifying oligos

Five years of preclinical oligo deals show high demand for ASO, siRNA and mRNA
BioCentury | Sep 28, 2017
Product R&D

Wave’s purity progress

Wave reveals how it makes its stereopure oligos
BioCentury | Feb 15, 2016
Product Development

High fidelity

How Wave's nucleic acid technology could confer an advantage in Huntington's
BioCentury | Aug 10, 2015
Clinical News

Kynamro mipomersen: Phase III data

BioCentury | Oct 16, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

BioCentury | Apr 14, 2014
Product Development

Family resemblance

Amgen, Regeneron PCSK9s look similar so far, but more data in LDL due this year
BioCentury | Nov 11, 2013
Company News

Isis Pharmaceuticals, SQI Diagnostics deal

BioCentury | Oct 24, 2013
Cover Story

A platform for RNA

Items per page:
1 - 10 of 123